Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer

Inclusion Criteria: Histologically confirmed adenocarcinoma of the prostate Must have undergone prior surgery or radiotherapy for the primary tumor Documented rising prostate-specific antigen (PSA) level, defined by the following criteria: Absolute level of PSA at least 0.2 ng/mL but less than 5.0 ng/mL Rising PSA level must be confirmed at least 1 week later Adequate PSA time points to calculate a PSA doubling time Gleason score no greater than 7 Age 18 and over Performance status ECOG 0-1 Life expectancy at least 6 months No other malignancy within the past 5 years except nonmelanoma skin cancer No other serious concurrent systemic medical disorders that would preclude study compliance No known allergy to pomegranate juice More than 4 weeks since prior participation in another experimental study Exclusion Criteria: nodal involvement evidence of metastatic disease prior hormonal therapy concurrent hormonal therapy for rising PSA levels after initial therapy for prostate cancer concurrent participation in another experimental study other concurrent systemic or local therapy for prostate cancer initiation or discontinuation of any new nutritional or dietary supplements during study participation